Shire, the Irish pharmaceutical company that specializes in the treatment of rare diseases, bought the American group NPS Pharmaceuticals in February 2015 for US$5.2 billion. There have been other financial deals like this recently, always involving amounts in the billions of dollars. For some pharmaceutical companies, developing treatments for...
Editorial Spring is here! We are full of projects for our various events: the Machu Picchu challenge, the Défi Ataxie cycling event , the various regional editions of the Walk to Fight Familial Ataxias, etc. Through these activities, we hope to reach a large number of participants across Quebec and...
Do you have a Facebook profile or a Twitter account and do you spend a certain number of hours on it each week? On there you share your news, your photos, your moods with others (loved ones, colleagues, true friends and Facebook friends.) Did you know that your social...
Publication of Jacques P. Tremblay’s team. AAV9 frataxin Friedreich ataxia An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models
28 February 2015 marks the eighth international Rare Disease Day coordinated by EURORDIS. On and around this day hundreds of patient organisations from more than 80 countries and regions worldwide are planning awareness-raising activities around the slogan Day-by-day, hand-in-hand.
The Relentless Work Editorial This is our second edition of the year, the first having come out in January. A lack of texts and resources is responsible for this long break. Here is some recent news I’d like to share. A few weeks ago, during the annual general meeting, a...
Welcome the new logo of Ataxia Canada. Please note that it is protected by copyright. Read the terms of use of the Ataxia Canada’s logo before using it.
